EMA对CYP抑制介导药物相互作用预测的资格认证意见:对ICH M15时代PBPK可信度评估的启示
本文解读EMA对Simcyp Simulator(V19R1)预测CYP介导DDI的资格认证意见,该意见涵盖6种酶、竞争性抑制和机制性抑制、受害药和肇事药及3种使用情境,246个预测中98.8%在2倍误差内。作者将该意见映射至ICH M15可信度概念,提出整合平台证据与药物特异性验证的操作框架。
要点
- Simcyp V19R1获EMA资格认证,用于预测CYP1A2、2C8、2C9、2C19、2D6、3A4/5介导的DDI。
- 资格认证数据显示246个预测中98.8%落在观测值2倍范围内。
- 该意见早于ICH M15,未提供与M15可信度概念的映射或平台证据外推方法。
核心结论
- EMA资格认证意见支持Simcyp V19R1在特定使用情境下预测CYP抑制介导的DDI,但需结合ICH M15框架将平台级证据扩展至具体研究药物。
研究设计与样本
- 本文为对EMA资格认证意见的解读与分析,并提出将资格认证证据映射至ICH M15可信度概念的方法学框架。
主要发现
- 资格认证数据涵盖6种CYP酶、竞争性抑制和机制性抑制、受害药和肇事药及3种使用情境。
- 三个使用情境下预测性能一致,平均倍数误差接近1,绝对平均倍数误差范围为1.23至1.25。
- 246个预测中98.8%落在观测值的2倍范围内。
关键数值与推荐
- 绝对平均倍数误差范围为1.23至1.25(三个使用情境)。
- 246个预测中98.8%在观测值2倍范围内。
临床怎么用
- 临床药学智能体可参考该资格认证意见,在ICH M15框架下评估PBPK模型对CYP抑制介导DDI预测的可信度。
- 应将平台级资格认证证据与药物特异性验证、预测性能、不确定性表征和前瞻性应用相结合。
局限性
- 该资格认证意见早于ICH M15,未提供与ICH M15可信度概念的映射或平台证据外推至具体研究药物的操作基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical pharmacology and pharmacometrics teams are now being encouraged to implement the ICH M15 framework in drug development to support model-informed decisions in regulatory submissions. Although model performance is an important component of model evaluation, regulatory confidence also depends on the intended context of use (CoU) and the supporting level of evidence. This is particularly relevant for physiologically based pharmacokinetic (PBPK) modeling, where increasing regulatory application has strengthened the need for structured approaches to evaluate predictive performance, extrapolation, uncertainty, and model applicability. The Simcyp Simulator (V19R1) was recently qualified by the EMA for prediction of CYP-mediated drug-drug interactions (DDIs) involving six enzymes (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5), competitive inhibition, and mechanism-based inhibition for both victim and perpetrator drugs across three CoUs. Qualification data demonstrated consistent predictive performance across the three CoUs, with average fold errors close to unity, absolute average fold errors ranging from 1.23 to 1.25, and 98.8% of 246 predictions falling within 2-fold of observed values. The opinion predates ICH M15; however, it does not provide either a mapping to its credibility concepts or an operational basis for extending platform-level evidence to a specific investigational drug. We address this gap with an explicit mapping of the qualification opinion onto ICH M15 credibility concepts and an integrated approach linking qualification evidence, drug-specific validation, predictive performance, uncertainty characterization, and prospective application, illustrating how confidence in PBPK-supported regulatory decisions can be established within an ICH M15-aligned framework.
引用
- Rowland Yeo, Neuhoff, Hatley, et al. The EMA Qualification Opinion for CYP Inhibition-Mediated Drug-Drug Interaction Predictions: Implications for PBPK Credibility Assessment in the Era of ICH M15. Clin Pharmacol Ther. 2026. PMID: 42934176. doi:10.1002/cpt.70533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。